Desvenlafaxine leads to fewer, less severe episodes
16 mar 2009-- Menopausal women who experience daily moderate to severe hot flushes can reduce the symptom by daily doses of the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (desvenlafaxine succinate), according to research published in the March issue of the American Journal of Obstetrics & Gynecology.
David F. Archer, M.D., of Eastern Virginia Medical School in Norfolk, and colleagues conducted a 26-week, placebo-controlled, double-blind trial of the medication with 567 postmenopausal women who reported having 50 or more hot flushes per week. The women were randomly assigned to receive desvenlafaxine (100 or 150 mg dose) or placebo. For women treated with desvenlafaxine, the mean number of moderate to severe hot flushes per day at week 12 declined from 10.8 to 4.3 (100 mg/d) and from 10.3 to 3.5 (150 mg/d), the researchers report. Women treated with placebo experienced a decrease from 10.6 to 5.6 hot flushes per day. The average daily severity of hot flushes also decreased more significantly at weeks 4 and 12 with desvenlafaxine than with placebo. Of the desvenlafaxine-treated women, 28.5 percent discontinued the medication because of unspecified adverse events, compared with 8.9 percent of placebo-treated women, the investigators found. "The results of this randomized, double-blind, placebo-controlled trial indicates that desvenlafaxine is an effective therapy for moderate to severe vasomotor symptoms associated with menopause," the authors write. The trial was supported by Wyeth Research, and several of the study authors report current or former relationships with Wyeth.
No comments:
Post a Comment